肿瘤化疗相关性血小板减少症(CIT)药物治疗新进展

New Progress in Drug Therapy of Tumor Chemotherapy-Associated Thrombocytopenia(CIT)

化疗相关性血小板减少症(Chemotherapy-induced thrombocytopenia,CIT)是肿瘤患者化疗的常见不良反应,其不仅导致患者外周血血小板减少,增加患者出现自发性出血的风险,而且延长化疗周期从而降低化疗治疗效果,不利于肿瘤患者实现长期生存目标。每年均有不少中西医学者对CIT的药物治疗进行大量临床研究,在预防性使用、西药联用、中西药联用及患者实际获益对比等方面涌现大量临床数据,本文重点对2019年以来的CIT治疗中西医药物最新临床研究进展进行综述,以期为临床医师选用CIT治疗药物提供参考。

Chemotherapy-induced thrombocytopenia(CIT)is a common adverse reaction of chemotherapy in cancer patients,which not only leads to peripheral blood thrombocytopenia and increases the risk of spontaneous bleeding,but also prolongs the chemotherapy cycle so as to reduce the effect of chemotherapy treatment,which is not conducive to the realization of long-term survival goals in cancer patients.Every year,many scholars of traditional Chinese and western medicine have conducted a large number of clinical studies on the drug treatment of CIT,and a large number of clinical data have emerged in terms of preventive use,combination of western medicine,combination of traditional Chinese and western medicine and comparison of actual benefits of patients.This article focuses on reviewing the latest clinical research progress of CIT in the treatment of traditional Chinese and western medicine drugs since 2019,in order to provide a reference for clinicians to select CIT therapeutic drugs.